Tuan Vu, MD

Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.

Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.